

Specimen ID: Control ID: Acct #: Walk-In Lab, LLC VART verified Phone: (800) 539-6119 Rte: 00

Patient Details

Specimen Details

Physician Details

Alternate Patient ID: Fasting:

General Comments & Additional

Information Alternate Control Number:

Total Volume: Not Provided

Ordered Items

N-Telopeptide, Urine (Serial)

TESTS	RESULT	FLAG	UNITS	REF	ERENCE	INTERVAL	LAB
N-Telopeptide, Urine (Seria	1)						
N-telopeptide	271		nmol BC	E	Not E	stab.	01
Creatinine, Urine	43.2		mg/dL		Not E	stab.	02
N-telo/Creat. Ratio	71		nM BCE/mM	Cr	0	-89	
Interpretive Guide:							01

The N-telopeptide and Creatinine are used to calculate the N-telo/Creat. Ratio which is referred to as "NTx". Suggested guidelines for the clinical use of NTx are as follows:

Menopausal Women not on Hormone Replacement Therapy (HRT): Women with a baseline NTx value >38 are at significant risk for a decrease in bone mineral density (BMD) after 1 year compared to women on HRT. The probability of a decline in BMD increases with NTx value as follows: (1):

Baseline NTx Probability of Decrease in BMD 18-38 1.4 p=0.28 38-51 2.5 p=0.03 51-67 3.8 p=0.0006 67-188 17.3 p=0.0001

- 2. Menopausal Women Receiving Antiresorptive Therapy: The probability that treatment is effective after three months is increased when the measured NTx value is <or=38 nM BCE/mM CRT, or NTx has decreased >or=30% from baseline.[1]
- 3. Patients with Paget's Disease of Bone:
 The probability that treatment is effective after one
 month is increased when the measured NTx value is within
 the reference range, or NTx has decreased >or=30%
 from baseline.[2]
 - Chesnut CH, Bell NH, Clark GS, et al. Am J Med, 102:29-37,1997. (1):M757, 1996.
 - 2. Bone H, Tucci J, et al. J Bone Min Res.11(1):M757,1996

PDF . 03



PatientReport

Patient:
DOB: Patient ID: Control ID:

Specimen ID: Date collected:

TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB

Please note reference interval change

For inquiries, the physician may contact Branch: 504-828-2666 Lab: 800-762-4344

